INOVIO PHARMACEUTICALS, INC. 8-K

What Happened
Inovio Pharmaceuticals, Inc. (INO) notified Oppenheimer & Co. Inc. on April 1, 2026 that it has suspended and terminated the prospectus dated August 13, 2024 that supported its "at-the-market" (ATM) sales program. The Sales Agreement with Oppenheimer remains in effect, but the company will not sell any shares under the Agreement unless and until a new prospectus is filed.

Key Details

• The company announced the change on April 1, 2026 via an Item 8.01 8-K filing.
• As of April 1, 2026, Inovio had issued and sold 1,319,644 shares under the ATM program for aggregate gross proceeds of $3.2 million (before commissions and offering expenses).
• The Sales Agreement with Oppenheimer (entered August 13, 2024) remains in full force and was not terminated—only the supporting prospectus was suspended/terminated.
• A new prospectus must be filed before any further ATM sales can occur.

Why It Matters
Suspending the ATM prospectus pauses Inovio’s ability to raise cash by continuously selling shares through the market under the existing prospectus. Investors should note the company has already raised about $3.2 million gross under the program but now needs a new prospectus to resume sales, which could affect near-term financing flexibility. The underlying sales agreement remains valid, so the company could resume ATM offerings once it files an updated prospectus.